Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 155

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 155
---
 board of directors authorized Aadi to enter into the proposed non-binding term sheet on the terms presented.

On August 21, 2024, Dr. Lennon signed on behalf of Aadi and delivered to WuXi Biologics a final term sheet (the “Term Sheet”) which
reflected the terms set forth in the August 18 Term Sheet. On August 27, 2024, representatives of WuXi Biologics countersigned the Term Sheet and delivered it to representatives of Aadi.

On August 22, 2024, representatives of Aadi, Wilson Sonsini and WuXi Biologics met via videoconference to discuss intellectual property due diligence
related to the ADC Programs.

On August 22, August 29 and September 12, 2024, the Aadi management team presented to the Strategic
Transaction Committee regarding Aadi’s ongoing confirmatory due diligence of the ADC Programs and related items, including, among other things, anticipated development timelines and resource and budget needs.

On September 5 and September 11, 2024, representatives of Aadi, WuXi Biologics, Hangzhou DAC and their respective legal counsel met via
videoconference to discuss intellectual property due diligence related to the ADC Programs, including the CPT113 linker-payload system developed by Hangzhou DAC.

On September 9, 2024, representatives of Aadi shared with representatives of WuXi Biologics a draft license agreement between Aadi and WuXi Biologics in
respect of the ADC Programs as contemplated by the Term Sheet (the “License Agreement”).

On September 11, 2024, Aadi entered into a first
amendment to the mutual confidentiality agreement with WuXi Biologics and Hangzhou DAC which expanded the range of persons allowed access to confidential information to include actual and/or potential investors in Aadi.

On September 16, 2024, Aadi’s board of directors held a virtual meeting with Aadi’s management and representatives of Leerink Partners and
Wilson Sonsini. At the meeting, Aadi’s management presented regarding the status of the negotiation of the License Agreement and related transactions, including a potential PIPE (private investment in public equity) financing to support license
payments to WuXi Biologics under the License Agreement and also capitalize the business following the execution of the License Agreement. In addition, management and Leerink Partners discussed the status of the dissolution analysis scenario to be
presented in full at a future board meeting. With respect to the PIPE Financing,